Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SciSparcSPRC +0.30%39 Market Cap is $3.88 Mil as of Aug. 28, 2026. GuruFocus rates SPRC with a GF Score™ of 39/100 and a GF Value™ of $3.03 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 1,421 Biotechnology companies, SciSparc ranks worse than 93.03% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). SciSparc's share price for the quarter that ended in Dec. 2025 was $12.24. SciSparc's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 0.04 Mil. Therefore, SciSparc's market cap for the quarter that ended in Dec. 2025 was $0.50 Mil.
SciSparc's quarterly market cap
declined
from Dec. 2024 ($3.88 Mil) to Jun. 2025 ($3.47 Mil) and
declined
from Jun. 2025 ($3.47 Mil) to Dec. 2025 ($0.50 Mil).
SciSparc's annual market cap
increased
from Dec. 2023 ($3.69 Mil) to Dec. 2024 ($3.88 Mil) but then
declined
from Dec. 2024 ($3.88 Mil) to Dec. 2025 ($0.50 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. SciSparc's Enterprise Value for Today is $0.56 Mil.
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
SciSparc Market Cap Related Terms
SciSparc Market Cap Historical Data
* Premium members only.
The historical data trend for SciSparc's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, SciSparc's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SciSparc Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SciSparc's Market Cap distribution charts can be found below:
* The bar in red indicates where SciSparc's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
SciSparc's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SciSparc (SPRC) has a Market Cap of $3.88 Mil as of Aug. 28, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on SciSparc and its competitors. According to the industry distribution chart, SciSparc ranks #1322 out of 1421 companies in the Biotechnology industry, placing it in the top 93%.
Is SciSparc's Market Cap too high?
SciSparc's current Market Cap is $3.88 Mil. The Biotechnology industry median Market Cap is 122.85. SciSparc's value of $3.88 Mil is 96.8% below this industry median. Based on the distribution chart, SciSparc ranks #1322 out of 1421 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, SciSparc has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SciSparc's Market Cap compare to ACUT and ONCO?
According to the Biotechnology industry distribution chart, SciSparc ranks #1322 out of 1421 companies for Market Cap. This places SciSparc in the lower half of its industry. The industry median Market Cap is 122.85. SciSparc's value of $3.88 Mil is 96.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 122.85, based on 1,421 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SciSparc's current Market Cap of $3.88 Mil is 96.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on SciSparc and its competitors. For the Biotechnology industry, the median Market Cap is 122.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SciSparc's current Market Cap is $3.88 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SciSparc stock overvalued right now?
Based on GuruFocus' analysis, SciSparc (SPRC) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.03, compared to a current price of $6.67 — trading 120.1% above its estimated fair value. The current Market Cap is $3.88 Mil and 96.8% below the Biotechnology industry median of 122.85. SciSparc's overall GF Score™ is 39/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For SciSparc (SPRC), the current Market Cap is $3.88 Mil as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SciSparc (SPRC) Overvalued in 2026?
Based on GuruFocus' analysis, SciSparc stock appears to be overvalued.
The current stock price of $6.67 is trading 120.1% above its estimated GF Value™ of $3.03.
GuruFocus considers SciSparc to be Significantly Overvalued.
Key valuation signals for SPRC:
Market Cap: $3.88 Mil
GF Value™: $3.03 vs. price of $6.67 (120.1% above fair value)
Industry Position: 96.8% below the Biotechnology median (#1322 of 1421)
No single metric tells the full story. See the SPRC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two operating reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.
39GF Score
Get the complete analysis for SPRC
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SPRC has been successfully added to your 
